The adjusted 3-year survival probability increased from 19.2% to 27.6%. US patients with metastatic urothelial cancer have seen improvements in survival since immune checkpoint inhibitors (ICIs) and ...
The 2026 GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Tyler F. Stewart ...
Long-term data from a prospective phase 2 trial show neoadjuvant cisplatin-based chemotherapy before nephroureterectomy provides durable survival benefits in high-risk, nonmetastatic UTUC. Neoadjuvant ...
Induction Yervoy (ipilimumab) plus Opdivo (nivolumab) followed by consolidative chemoradiotherapy demonstrated bladder ...
Neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy with pelvic lymph node dissection has been the standard of care for muscle-invasive bladder cancer for decades. The advent of ...
Late-breaking KEYNOTE-B15 data show KEYTRUDA ® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) significantly improved event-free survival, overall survival and pathologic complete response ...
Urothelium is the term for the mucous membrane that lines the urinary tract. This includes the renal pelvis, ureter, urinary bladder and the upper part of the urethra. In the vast majority of cases, ...
Neoadjuvant chemotherapy with a regimen of gemcitabine-cisplatin for high-risk upper tract urothelial carcinoma (UTUC) resulted in a high rate of downstaging, and should now be considered a new ...
Validation of Clinical Dynamic Contrast-Enhanced Magnetic Resonance Imaging Perfusion Modeling and Neoadjuvant Chemotherapy Response Prediction in Breast Cancer Using 18FDG and 64Cu-DOTA-Trastuzumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results